Title |
Cobalamin deficiency, hyperhomocysteinemia, and dementia
|
---|---|
Published in |
Neuropsychiatric Disease and Treatment, April 2010
|
DOI | 10.2147/ndt.s6564 |
Pubmed ID | |
Authors |
Steven F Werder |
Abstract |
Although consensus guidelines recommend checking serum B12 in patients with dementia, clinicians are often faced with various questions: (1) Which patients should be tested? (2) What test should be ordered? (3) How are inferences made from such testing? (4) In addition to serum B12, should other tests be ordered? (5) Is B12 deficiency compatible with dementia of the Alzheimer's type? (6) What is to be expected from treatment? (7) How is B12 deficiency treated? |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 2 | 22% |
United Kingdom | 2 | 22% |
France | 1 | 11% |
Spain | 1 | 11% |
Unknown | 3 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 7 | 78% |
Scientists | 1 | 11% |
Practitioners (doctors, other healthcare professionals) | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 100 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 2% |
Brazil | 1 | 1% |
Germany | 1 | 1% |
United Kingdom | 1 | 1% |
India | 1 | 1% |
Unknown | 94 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 17 | 17% |
Student > Master | 14 | 14% |
Student > Doctoral Student | 11 | 11% |
Other | 8 | 8% |
Student > Ph. D. Student | 8 | 8% |
Other | 23 | 23% |
Unknown | 19 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 37 | 37% |
Psychology | 11 | 11% |
Agricultural and Biological Sciences | 9 | 9% |
Nursing and Health Professions | 6 | 6% |
Neuroscience | 5 | 5% |
Other | 11 | 11% |
Unknown | 21 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 December 2022.
All research outputs
#1,970,414
of 25,483,400 outputs
Outputs from Neuropsychiatric Disease and Treatment
#248
of 3,137 outputs
Outputs of similar age
#6,858
of 103,667 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#1
of 15 outputs
Altmetric has tracked 25,483,400 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,137 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 103,667 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.